Harrow Inc
HROW39.010USD
+0.220+0.57%
Market hours （ET）Quotes delayed by 15 min
1.43BMarket Cap
LossP/E TTM
More Details of Harrow Inc Company
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Company Info
Ticker SymbolHROW
Company nameHarrow Inc
IPO dateFeb 08, 2013
CEOMr. John P. Saharek
Number of employees382
Security typeOrdinary Share
Fiscal year-endFeb 08
Address1A Burton Hills Blvd
CityNASHVILLE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code37215
Phone16157334731
Websitehttps://www.harrow.com/
Ticker SymbolHROW
IPO dateFeb 08, 2013
CEOMr. John P. Saharek
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
10.55%
Baum (Mark L)
7.80%
BlackRock Institutional Trust Company, N.A.
6.09%
Private Capital Management
5.26%
The Vanguard Group, Inc.
5.03%
Other
65.27%
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
10.55%
Baum (Mark L)
7.80%
BlackRock Institutional Trust Company, N.A.
6.09%
Private Capital Management
5.26%
The Vanguard Group, Inc.
5.03%
Other
65.27%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
18.79%
Investment Advisor
18.12%
Hedge Fund
17.30%
Individual Investor
15.72%
Research Firm
2.46%
Bank and Trust
0.35%
Pension Fund
0.29%
Sovereign Wealth Fund
0.07%
Insurance Company
0.03%
Other
26.87%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
345
26.63M
72.57%
-2.99M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
2023Q2
265
25.64M
85.30%
+312.85K
2023Q1
246
23.86M
79.81%
+1.57M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Opaleye Management Inc.
3.94M
10.72%
-4.80K
-0.12%
Jun 04, 2025
Baum (Mark L)
2.60M
7.08%
+461.94K
+21.61%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
2.27M
6.2%
-1.07K
-0.05%
Mar 31, 2025
Private Capital Management
1.89M
5.15%
+195.64K
+11.54%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
5.07%
-6.65K
-0.36%
Mar 31, 2025
Kaufman (Daniel)
1.68M
4.59%
-222.91K
-11.69%
Aug 12, 2024
Braidwell LP
956.84K
2.61%
+49.80K
+5.49%
Mar 31, 2025
Geode Capital Management, L.L.C.
774.08K
2.11%
+52.97K
+7.35%
Mar 31, 2025
Boll (Andrew R)
777.84K
2.12%
+209.75K
+36.92%
Apr 21, 2025
State Street Global Advisors (US)
786.48K
2.14%
-41.22K
-4.98%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
SPDR S&P Pharmaceuticals ETF
1.81%
Invesco Dorsey Wright Healthcare Momentum ETF
1.59%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.12%
iShares U.S. Pharmaceuticals ETF
0.49%
First Trust Small Cap Growth AlphaDEX Fund
0.37%
Invesco Dorsey Wright SmallCap Momentum ETF
0.36%
iShares Micro-Cap ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
Fidelity Small-Mid Multifactor ETF
0.1%
View more
SPDR S&P Pharmaceuticals ETF
Proportion1.81%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.59%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.12%
iShares U.S. Pharmaceuticals ETF
Proportion0.49%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.37%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.36%
iShares Micro-Cap ETF
Proportion0.22%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.11%
Fidelity Small-Mid Multifactor ETF
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
